Lyka LabsBOM:500259 +0.78%60 Gross Margin % is 60.65% as of Mar. 2026, which is 15% above its 10-year median of 52.83. GuruFocus rates BOM:500259 with a GF Score™ of 60/100 and a GF Value™ of ₹127.26 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 732 Biotechnology companies, Lyka Labs ranks better than 50.14% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Lyka Labs's Gross Profit for the
three
months ended in Mar. 2026 was ₹170 Mil. Lyka Labs's Revenue for the
three
months ended in Mar. 2026 was ₹280 Mil. Therefore, Lyka Labs's Gross Margin % for the quarter that ended in Mar. 2026 was 60.65%.
The historical rank and industry rank for Lyka Labs's Gross Margin % or its related term are showing as below:
BOM:500259'
s Gross Margin % Range Over the Past 10 Years
Min: 35.35 Med: 52.83 Max: 70.97
Current: 60.92
During the past 13 years, the highestGross Margin % of Lyka Labs was 70.97%. The lowest was 35.35%. And the median was 52.83%.
BOM:500259's Gross Margin % is ranked better than 50.14% of 732
companies
in the Biotechnology industry
Industry Median: 60.905
vs BOM:500259: 60.92
Lyka Labs had a gross margin of 60.65% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Lyka Labs was 3.50% per year.
Lyka Labs (BOM:500259) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Lyka Labs had a gross margin of 60.65% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Lyka Labs Gross Margin % Related Terms
Lyka Labs Gross Margin % Historical Data
* Premium members only.
The historical data trend for Lyka Labs's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:500259 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Lyka Labs's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyka Labs Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyka Labs's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Lyka Labs's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Lyka Labs (BOM:500259) has a Gross Margin % of 60.65% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Lyka Labs and its competitors. This is 15% above median its historical median of 52.83. Over the past decade, Lyka Labs' Gross Margin % has ranged from 35.35 to 70.97. According to the industry distribution chart, Lyka Labs ranks #365 out of 732 companies in the Biotechnology industry, placing it in the top 49.9%.
Is Lyka Labs' Gross Margin % too high?
Lyka Labs' current Gross Margin % of 60.65% is 15% above median its 10-year median of 52.83. Over the past 10 years, this metric has ranged from a low of 35.35 to a high of 70.97. The Biotechnology industry median Gross Margin % is 60.91. Lyka Labs' value of 60.65% is 0.4% below this industry median. Based on the distribution chart, Lyka Labs ranks #365 out of 732 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lyka Labs has a GF Score™ of 60/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lyka Labs' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lyka Labs ranks #365 out of 732 companies for Gross Margin %. This puts Lyka Labs in the upper half of its industry. The industry median Gross Margin % is 60.91. Lyka Labs' value of 60.65% is 0.4% below this benchmark. Historically, Lyka Labs' own Gross Margin % has ranged from 35.35 to 70.97 over the past decade. While the company's 10-year median is 52.83 vs. the industry median of 60.91, Lyka Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lyka Labs's current Gross Margin % of 60.65% is 0.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Lyka Labs and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lyka Labs's current Gross Margin % is 60.65%, which is 15% above median its own 10-year median of 52.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyka Labs stock overvalued right now?
Based on GuruFocus' analysis, Lyka Labs (BOM:500259) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹127.26, compared to a current price of ₹72.36 — trading 43.1% below its estimated fair value. The current Gross Margin % is 60.65%, which is 15% above median its 10-year median of 52.83 and 0.4% below the Biotechnology industry median of 60.91. Lyka Labs' overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Lyka Labs (BOM:500259), the current Gross Margin % is 60.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lyka Labs (BOM:500259) Overvalued in 2026?
Based on GuruFocus' analysis, Lyka Labs stock appears to be undervalued.
The current stock price of ₹72.36 is trading 43.1% below its estimated GF Value™ of ₹127.26.
GuruFocus considers Lyka Labs to be Significantly Undervalued.
Key valuation signals for BOM:500259:
Gross Margin %: 60.65% (15% above median its 10-year median of 52.83)
GF Value™: ₹127.26 vs. price of ₹72.36 (43.1% below fair value)
Industry Position: 0.4% below the Biotechnology median (#365 of 732)
No single metric tells the full story. See the BOM:500259 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment which is pharmaceuticals. The Company has a presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.
60GF Score
Get the complete analysis for BOM:500259
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500259 has been successfully added to your 
